HBsAg ELISA Kit

HBsAg ELISA Kit
  • Measures the Hepatitis B surface antigen (HBsAg) in purified virus or unpurified viral supernatant
  • Detection limit of approximately 1 ng/ml
  • HBsAg standard included

 

Video: Color Development in an ELISA

Email To BuyerPrint this PageCopy Link
Ordering

Please contact your distributor for pricing.

QuickTiter™ Hepatitis B Surface Antigen (HBsAg) ELISA Kit
Catalog Number
VPK-5004
Size
96 assays
Detection
Colorimetric
Manual/Data Sheet Download
SDS Download
Price
$875.00
QuickTiter™ Hepatitis B Surface Antigen (HBsAg) ELISA Kit
Catalog Number
VPK-5004-5
Size
5 x 96 assays
Detection
Colorimetric
Manual/Data Sheet Download
SDS Download
Price
$3,795.00
Product Details

The Hepatitis B virus (HBV) causes Hepatitis B, an infection of the liver, and is transmitted through blood or bodily fluids. Markers of HBV infection include the surface antigen (HBsAg), the e antigen (HBeAg), and the core antigen (HBcAg), which are often used for detection.

Our HBsAg ELISA is a sandwich ELISA that is designed for detection and quantitation of Hepatitis B surface antigen in purified virus or unpurified viral supernatant. This assay uses an anti-HBsAg antibody coated plate that binds to any HBsAg present in the sample. A FITC-conjugated anti-HBsAg antibody is then added, which binds to HBsAg sample-antibody complex. This is detected by the addition of an HRP-conjugated anti-FITC antibody.  HBsAg levels in unknown samples are calculated based on the HBsAg standard curve.

Recent Product Citations
  1. Khan, A. et al. (2024). Seroprevalence of Hepatic Viruses and Associated Risk Factors Among Rehabilitated Patients During the Post-Addictive Phase. JHRR. 4(3):1-5. doi: 10.61919/jhrr.v4i3.1370.
  2. Duraisamy, G.S. et al. (2022). Selected ginsenosides interfere efficiently with hepatitis B virus mRNA expression levels and suppress viral surface antigen secretion. Heliyon. 8(9):e10465. doi: 10.1016/j.heliyon.2022.e10465.
  3. Du, N. et al. (2022). CircRNA circBACH1 facilitates hepatitis B virus replication and hepatoma development by regulating the miR-200a-3p/MAP3K2 axis. Histol Histopathol. doi: 10.14670/HH-18-452.
  4. Chauhan, R. et al. (2021). Efficient Inhibition of Hepatitis B Virus Replication and cccDNA Formation by HBV Ribonuclease H Inhibitors During Infection. Antimicrob Agents Chemother. doi: 10.1128/AAC.01460-21.
  5. Domfeh, S.A. et al. (2021). Cryptolepine and Nibima inhibit hepatitis B virus replication. Sci Afr. doi: 10.1016/j.sciaf.2021.e00942.
  6. Le, C. et al. (2021). In Vitro Infection with Hepatitis B Virus Using Differentiated Human Serum Culture of Huh7.5-NTCP Cells without Requiring Dimethyl Sulfoxide. Viruses. 13(1):E97. doi: 10.3390/v13010097.
  7. Wang, W. et al. (2020).  A long-acting 3TC ProTide nanoformulation suppresses HBV replication in humanized mice. Nanomedicine. doi: 10.1016/j.nano.2020.102185.
  8. Zhao, Y. et al. (2019). MiR-3613-3p impairs IFN-induced immune response by targeting CMPK1 in chronic hepatitis B. Infect Genet Evol. 103919. doi: 10.1016/j.meegid.2019.103919.
  9. Hussan, A.A. et al. (2018). Prevelance Of Cholelithiasis In Iraqi Patients with Hepatitis B Infection. Pak. J. Biotechnol. 15(2):391-397.
  10. Kim, S.H. (2017). ELISA for Quantitative Determination of Hepatitis B Virus Surface Antigen. Immune Netw. 17(6):451-459. doi: 10.4110/in.2017.17.6.451.